The Evidence Pack: How the Pentagon's Expanded 1260H Procurement Ban Works

On June 8, 2026, the U.S. Department of Defense published a significantly expanded iteration of its Section 1260H list, identifying 188 entities as "Chinese military companies" operating within the United States. The update added 65 new organizations, sweeping in globally recognized consumer and technology brands such as Alibaba, Baidu, and electric vehicle manufacturer BYD.[1][2][3][4]

Unlike traditional sanctions administered by the Treasury Department, the 1260H list was originally designed as a reputational mechanism. However, recent legislative updates have transformed it into a substantive legal barrier. This evidence pack examines the statutory framework, the evidentiary standards used for designation, and the cascading supply chain restrictions taking effect between 2026 and 2027.[4][5]

The primary claim underpinning the Pentagon's designations is that the listed entities actively participate in Beijing's "Military-Civil Fusion" (MCF) strategy. According to the Defense Department, this state-led initiative systematically erases the barrier between China's civilian research sectors and its military-industrial complex, ensuring the People's Liberation Army can access advanced technologies developed by ostensibly private firms.[1][2][5]

The statutory evidence required for a 1260H designation is broad. Under the National Defense Authorization Act (NDAA) for Fiscal Year 2021, an entity qualifies if it is engaged in commercial services or manufacturing and is either directly controlled by Chinese state security apparatuses or identified as an MCF contributor.[4][5]

Legal analyses note that the definition of an MCF contributor includes any company receiving "assistance, operational direction, or policy guidance" from the Chinese government. This low evidentiary threshold allows the Pentagon to designate publicly traded, non-state-owned enterprises based on regulatory affiliations or state subsidies.[1][4][5]

For example, the inclusion of e-commerce giant Alibaba and search provider Baidu is reportedly linked to their affiliations with China's Ministry of Industry and Information Technology. Similarly, robotics firm Unitree was designated after the Pentagon cited its classification by the Chinese state as a highly innovative enterprise critical to national supply chains.[1][3]

The most significant consequence of the updated list is a staggered, two-phase federal procurement ban codified in Section 805 of the FY 2024 NDAA. The first phase, which took effect on June 30, 2026, strictly prohibits the Defense Department from entering into or renewing direct contracts for goods, services, or technology with any 1260H-designated entity.[4][5]

The second phase, scheduled for June 30, 2027, introduces a far more complex evidentiary and compliance challenge: an indirect procurement ban. After this date, the Pentagon cannot contract for any goods or services that "include goods or services produced or developed by" a 1260H entity. This forces primary defense contractors to audit their entire supply chains to ensure no components originate from the blacklisted firms.[4][5]

The evidentiary burden for this indirect ban remains a point of high uncertainty. Supply chain experts note that tracing sub-components—such as specific microchips, battery cells, or open-source software modules—down to tier-three or tier-four suppliers will require unprecedented diligence from U.S. defense contractors.[4]

Beyond traditional defense procurement, the 1260H list now intersects directly with U.S. biosecurity policy. The June 2026 update prominently added several biotechnology firms, including WuXi AppTec, Complete Genomics, and Novogene.[4][7]

According to guidance from research institutions, these additions serve as a trigger mechanism for the BIOSECURE Act. Once fully implemented, the Act will prohibit federal agencies and federally funded research organizations from procuring biotechnology equipment or services from these designated "companies of concern," forcing a massive realignment in pharmaceutical supply chains.[4][7]

The evidence supporting these designations is strongly contested by the targeted companies. In public statements, Alibaba asserted that it is not a military company, is not part of any military-civil fusion strategy, and that there is "no basis" for its inclusion. BYD similarly rejected the designation, stating that the Pentagon's determination "seriously contradicts the facts."[1][3]

There is legal precedent for challenging the Pentagon's evidentiary standards. In 2021, Chinese smartphone manufacturer Xiaomi successfully sued the U.S. government to be removed from an earlier iteration of the list, arguing that the Defense Department failed to provide sufficient evidence of military control. Several newly listed firms have indicated they are exploring similar legal avenues.[2][3]

The geopolitical reaction to the expanded list has been swift and retaliatory. The Chinese Ministry of Commerce accused Washington of overstretching the concept of national security to suppress global competition and disrupt international supply chains.[3][6]

In direct response, Beijing imposed its own export controls and sanctions on dozens of U.S. entities. The countermeasures specifically targeted American defense and aerospace contractors, including Ball Aerospace, Oshkosh Defense, and Aveox Inc., prohibiting them from importing dual-use items originating from China.[6]

Ultimately, the 1260H list represents a fundamental shift in how the U.S. government evaluates supply chain risk. By moving away from strict definitions of state ownership toward a broader assessment of state influence and technological dual-use potential, the Pentagon has effectively mandated a decoupling of U.S. defense procurement from China's leading technology sectors.[2][4]